Page last updated: 2024-10-30

losartan and Chagas Cardiomyopathy

losartan has been researched along with Chagas Cardiomyopathy in 1 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Chagas Cardiomyopathy: A disease of the CARDIAC MUSCLE developed subsequent to the initial protozoan infection by TRYPANOSOMA CRUZI. After infection, less than 10% develop acute illness such as MYOCARDITIS (mostly in children). The disease then enters a latent phase without clinical symptoms until about 20 years later. Myocardial symptoms of advanced CHAGAS DISEASE include conduction defects (HEART BLOCK) and CARDIOMEGALY.

Research Excerpts

ExcerptRelevanceReference
"In patients with Chagas' disease, these drugs exerted a controversial impact on cytokine and hormone levels, and a limited effect on cardiovascular function."2.61Could angiotensin-modulating drugs be relevant for the treatment of Trypanosoma cruzi infection? A systematic review of preclinical and clinical evidence. ( Diniz, LF; Gonçalves, RV; Lia Mazzeti, A; Mendonça, AAS; Novaes, RD; Souza-Silva, TG, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Souza-Silva, TG1
Diniz, LF1
Lia Mazzeti, A1
Mendonça, AAS1
Gonçalves, RV1
Novaes, RD1

Reviews

1 review available for losartan and Chagas Cardiomyopathy

ArticleYear
Could angiotensin-modulating drugs be relevant for the treatment of Trypanosoma cruzi infection? A systematic review of preclinical and clinical evidence.
    Parasitology, 2019, Volume: 146, Issue:7

    Topics: Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Captopril; CD8-Positive T-Lymphocyt

2019